Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, today announces FDA clearance of the new Cochlear® Osia® 3 Sound Processor
✦ Clinical Takeaway ✦
No actionable clinical practice change at this time; audiologists who fit Osia-family devices should monitor Cochlear's product training and candidacy criteria for the Osia 3 before transitioning fittings.
✦ Why It Matters ✦
FDA clearance of the Osia 3 expands the bone-anchored hearing device market and may give audiologists and patients a newer processor option within an established implant platform.
✦ Key Points ✦
- 01Cochlear Limited has received FDA clearance for the Osia 3 Sound Processor.
- 02The Osia 3 is an updated external processor in the existing Osia bone-anchored hearing system line.
- 03The device works via an implant that transmits sound vibrations through bone to the inner ear.
- 04No clinical outcome data or head-to-head comparison data were provided in this announcement.
- 05Announcement was made via a trade/industry channel (AudiologyOnline), indicating a commercial launch context.
✦ Claims & Evidence ✦
ClaimEvidenceSupport
The Osia 3 Sound Processor has received FDA clearance.
press releasesupportedThe Osia 3 is an updated implantable bone-anchored hearing device in the Osia product line.
press releaseunclear